Robert Azelby, EVP & Chief Commercial Officer at Juno Therapeutics, Inc. (JUNO), sold 9,694 shares at $85.77 ($831K) on 2018-02-08, disclosed to the SEC on 2018-02-09.
Open-market sale of $831k JUNO by EVP & Chief Commercial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.49 | 2,700 | $231K | 27.8% |
| 2 | $85.77 | 3,497 | $300K | 36.1% |
| 3 | $85.77 | 3,497 | $300K | 36.1% |
| Total | $85.69 avg | 9,694 | $831K | 100% |
| Filing → |
| JUNO | SELL | 2018-02-14 | $356K | — | Filing → |
| JUNO | SELL | 2018-02-02 | $715K | — | Filing → |
| JUNO | SELL | 2018-01-24 | $17.7M | — | Filing → |